[go: up one dir, main page]

PE20220711A1 - Derivados de 2-isoindol-1,3,4-oxadiazol utiles como inhibidores de la histona desacetilasa 6 (hdac6) - Google Patents

Derivados de 2-isoindol-1,3,4-oxadiazol utiles como inhibidores de la histona desacetilasa 6 (hdac6)

Info

Publication number
PE20220711A1
PE20220711A1 PE2022000460A PE2022000460A PE20220711A1 PE 20220711 A1 PE20220711 A1 PE 20220711A1 PE 2022000460 A PE2022000460 A PE 2022000460A PE 2022000460 A PE2022000460 A PE 2022000460A PE 20220711 A1 PE20220711 A1 PE 20220711A1
Authority
PE
Peru
Prior art keywords
optionally substituted
halogen atoms
group
isoindol
substituents selected
Prior art date
Application number
PE2022000460A
Other languages
English (en)
Inventor
Masahiro Ito
Hideyuki Sugiyama
Takeshi Yamamoto
Keiko Kakegawa
Jinxing Li
Junsi Wang
Takahito Kasahara
Masato Yoshikawa
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of PE20220711A1 publication Critical patent/PE20220711A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Referido a un compuesto de formula (I), donde R1 es (1) un grupo cicloalquilo C3-10 sustituido de manera opcional por 1 a 3 atomos de halogeno, (2) un grupo arilo C6-14 sustituido de manera opcional por 1 a 3 sustituyentes seleccionados entre (i) un atomo de halogeno, (ii) un grupo ciano y (iii) un grupo alquilo C1-6 sustituido de manera opcional por 1 a 3 atomos de halogeno, (3) un grupo heterociclico aromatico monociclico de 5 o 6 miembros sustituido de manera opcional por 1 a 3 sustituyentes seleccionados entre (i) un atomo de halogeno, (ii) un grupo alquilo C1-6 sustituido de manera opcional por 1 a 3 atomos de halogeno, y (iii) un grupo alcoxi C1-6, o (4) un grupo heterociclico no aromatico monociclico de 3 a 8 miembros, y R2 es (1) un grupo cicloalquilo C3-10 sustituido de manera opcional por 1 a 3 atomos de halogeno, (2) un grupo arilo C6-14 sustituido de manera opcional por 1 a 3 sustituyentes seleccionados entre un atomo de halogeno, y un grupo alquilo C1-6 sustituido de manera opcional por 1 a 3 atomos de halogeno, (3) un grupo heterociclico aromatico monociclico de 5 o 6 miembros sustituido de manera opcional por 1 a 3 sustituyentes seleccionados entre (i) un atomo de halogeno, (ii) un grupo alquilo C1-6 sustituido de manera opcional por 1 a 3 atomos de halogeno, y (iii) un grupo alcoxi C1-6, o (4) un grupo heterociclico no aromatico monociclico de 3 a 8 miembros, o una sal del mismo. Son compuestos preferidos: 6-[5-(Difluorometil)-1,3,4-oxadiazol-2-il]-2- [(1R,2R)-2-hidroxi-1,2-di(piridin-2-il)etil]-2,3-dihidro-1Hisoindol-1-ona; 6-[5-(Difluorometil)-1,3,4-oxadiazol-2-il]-2- [(1R,2R)-2-(5-fluoropiridin-2-il)-2-hidroxi-1-(piridin-2- il)etil]-2,3-dihidro-1H-isoindol-1-ona; 2-[(1R,2R)-1,2-Bis(5-fluoropiridin-2-il)-2- hidroxietil]-6-[5-(difluorometil)-1,3,4-oxadiazol-2-il]-2,3- dihidro-1H-isoindol-1-ona. Dichos compuestos tienen una accion inhibitoria de histona desacetilasa 6 (HDAC6) y son utiles para el tratamiento de enfermedades del sistema nervioso central, que incluyen enfermedades neurodegenerativas y similares.
PE2022000460A 2019-09-27 2020-09-24 Derivados de 2-isoindol-1,3,4-oxadiazol utiles como inhibidores de la histona desacetilasa 6 (hdac6) PE20220711A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019177815 2019-09-27
PCT/JP2020/037386 WO2021060567A1 (en) 2019-09-27 2020-09-24 2-isoindol-1,3,4-oxadiazole derivatives useful as hdac6 inhibitors

Publications (1)

Publication Number Publication Date
PE20220711A1 true PE20220711A1 (es) 2022-05-04

Family

ID=73040188

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022000460A PE20220711A1 (es) 2019-09-27 2020-09-24 Derivados de 2-isoindol-1,3,4-oxadiazol utiles como inhibidores de la histona desacetilasa 6 (hdac6)

Country Status (19)

Country Link
US (3) US11453661B2 (es)
EP (1) EP4034536A1 (es)
JP (1) JP7602546B2 (es)
KR (1) KR20220070465A (es)
CN (1) CN114846012B (es)
AR (1) AR120040A1 (es)
AU (1) AU2020353984B2 (es)
BR (1) BR112022005595A2 (es)
CA (1) CA3156060A1 (es)
CL (1) CL2022000763A1 (es)
CO (1) CO2022005059A2 (es)
EC (1) ECSP22026524A (es)
IL (1) IL291413B2 (es)
MX (1) MX2022003490A (es)
PE (1) PE20220711A1 (es)
PH (1) PH12022550748A1 (es)
TW (1) TWI882012B (es)
WO (1) WO2021060567A1 (es)
ZA (1) ZA202204666B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
CN114846012B (zh) * 2019-09-27 2024-01-26 武田药品工业株式会社 可用作hdac6抑制剂的2-异吲哚-1,3,4-噁二唑衍生物
BR112022011917A2 (pt) 2019-12-20 2022-09-06 Tenaya Therapeutics Inc Fluoroalquil-oxadiazois e seus usos
EP4326263A1 (en) 2021-04-23 2024-02-28 Tenaya Therapeutics, Inc. Hdac6 inhibitors for use in the treatment of dilated cardiomyopathy
MX2023012875A (es) 2021-05-04 2024-01-12 Tenaya Therapeutics Inc Inhibidores 2-fluoro alquil-l,3,4-oxadiazol-5-il-tiazol de hdac6 para su uso en el tratamiento de enfermedades metabólicas y hfpef.
CN114166824B (zh) * 2021-12-08 2024-01-23 桂林医学院 一种辅剂示踪分析保健品中药物含量的方法
EP4509506A1 (en) * 2022-04-15 2025-02-19 Suzhou Genhouse Bio Co., Ltd. Oxadiazole compound, pharmaceutical composition comprising same, and use thereof
WO2024196136A1 (ko) * 2023-03-21 2024-09-26 주식회사 비보존 Mglur5 및 hdac6의 이중 조절제 및 이의 용도
WO2025067416A1 (zh) * 2023-09-28 2025-04-03 勤浩医药（苏州）有限公司 一种hdac6抑制剂的结晶形式及其制备方法
WO2025215092A1 (en) 2024-04-10 2025-10-16 Institut National de la Santé et de la Recherche Médicale Selective hdac6 inhibitors for use in the treatment of myotonic dystrophy type 1

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030129724A1 (en) 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
ES2310213T3 (es) 2001-05-02 2009-01-01 The Regents Of The University Of California Procedimiento para tratar trastornos neurodegenerativos, psiquiatricos y otros trastornos con inhibidores de desacetilasa.
US20040142859A1 (en) 2002-05-02 2004-07-22 Steffan Joan S. Method for treating neurodegenerative, psychiatric, and other disorders with deacetylase inhibitors
US20050227915A1 (en) 2001-05-02 2005-10-13 Steffan Joan S Methods and reagents for treating neurodegenerative diseases and motor deficit disorders
AU2002340253C1 (en) 2001-10-16 2011-03-31 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases and cancer of the brain
NZ550185A (en) 2002-03-04 2008-10-31 Merck Hdac Res Llc Methods of inducing terminal differentiation Methods of inducing terminal differentiation
EP1488005A1 (fr) 2002-03-26 2004-12-22 Exhonit Therapeutics SA Histone deacetylase : nouvelle cible moleculaire de la neurotoxicite
US20040077591A1 (en) 2002-03-28 2004-04-22 The Brigham And Women's Hospital, Inc. Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and Alzheimer's Disease
ITMI20040876A1 (it) 2004-04-30 2004-07-30 Univ Degli Studi Milano Inibitori delle istone deacetilasi-hdac-quali agenti ipolipidemizzati per la terapia e la prevenzione dell'arteriosclerosi e malattie cardiovascolari
US20060018921A1 (en) 2004-07-16 2006-01-26 Baylor College Of Medicine Histone deacetylase inhibitors and cognitive applications
GT200500321A (es) 2004-11-09 2006-09-04 Compuestos y composiciones como inhibidores de proteina kinase.
CN101056632B (zh) * 2004-11-09 2011-12-07 Irm责任有限公司 用作蛋白激酶抑制剂的化合物和组合物
US20060135612A1 (en) 2004-12-17 2006-06-22 U.S. Department Of Veterans Affairs Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as amyotrophic lateral sclerosis (ALS), by using a HDAC inhibiting agent
US8999289B2 (en) 2005-03-22 2015-04-07 President And Fellows Of Harvard College Treatment of protein degradation disorders
AU2006272497B2 (en) 2005-07-27 2012-07-19 University Of Florida Research Foundation, Inc. Small compounds that correct protein misfolding and uses thereof
CA2621560A1 (en) 2005-09-07 2007-03-15 Braincells, Inc. Modulation of neurogenesis by hdac inhibition
WO2007049262A1 (en) 2005-10-27 2007-05-03 Berand Limited Methods and compositions for the promotion of neuronal growth and the treatment of asociality and affective disorders
CA2626897A1 (en) 2005-11-03 2007-05-18 Joshua Close Histone deacetylase inhibitors with aryl-pyrazolyl motifs
US20070207950A1 (en) 2005-12-21 2007-09-06 Duke University Methods and compositions for regulating HDAC6 activity
GB0612273D0 (en) 2006-06-21 2006-08-02 Friedrich Miescher Inst For Bi Prevention of muscle atrophy
US8088951B2 (en) 2006-11-30 2012-01-03 Massachusetts Institute Of Technology Epigenetic mechanisms re-establish access to long-term memory after neuronal loss
WO2008073733A1 (en) 2006-12-08 2008-06-19 Kalypsys, Inc. Salts of inhibitors of histone deacetylase for the treatment of disease
CA2671550A1 (en) 2006-12-15 2008-06-26 Novartis Ag Heterocycle compounds and methods of use thereof
WO2008126932A2 (en) 2007-04-09 2008-10-23 Riken Epigenetical regulation of brain plasticity
EP3103791B1 (en) 2007-06-27 2018-01-31 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
WO2009027349A2 (en) 2007-08-24 2009-03-05 Oryzon Genomics Sa Treatment and prevention of neurodegenerative diseases
US20090136461A1 (en) 2007-11-28 2009-05-28 Moon Suk Kim Neuronal differentiation method of adult stem cells using small molecules
AU2013203735A1 (en) * 2007-12-04 2013-05-02 F. Hoffmann-La Roche Ag Isoxazolo-pyridine derivatives
RU2012131164A (ru) * 2009-12-22 2014-01-27 Селджин Корпорейшн (метилсульфонил)этил-бензол-изоиндолиновые производные и их терапевтическое применение
KR101781663B1 (ko) 2010-01-13 2017-09-25 템페로 파마슈티칼즈, 인크. 히스톤 데아세틸라제 효소를 억제하기 위한 화합물 및 이를 제조하는 방법
US8981084B2 (en) 2010-01-13 2015-03-17 Tempero Pharmaceuticals, Inc. Oxadiazole HDAC inhibitors
WO2012018499A2 (en) 2010-08-05 2012-02-09 Acetylon Pharmaceuticals Specific regulation of cytokine levels by hdac6 inhibitors
US20130227717A1 (en) 2010-10-08 2013-08-29 Life Sciences Research Partners Vzw Hdac inhibitors to treat charcot-marie-tooth disease
US20130203735A1 (en) 2010-10-28 2013-08-08 John T. Sisko Caprolactam mglur5 receptor modulators
US9540395B2 (en) 2011-02-28 2017-01-10 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
EP2701699B1 (en) 2011-04-28 2019-10-16 The Broad Institute, Inc. Inhibitors of histone deacetylase
WO2012162535A1 (en) 2011-05-24 2012-11-29 Lixte Biotechnology, Inc. Use of phosphatase inhibitors or histone deacetylase inhibitors to treat diseases characterized by loss of protein function
WO2013006408A1 (en) 2011-07-01 2013-01-10 Tempero Pharmaceuticals, Inc. Compounds and methods
US9056843B2 (en) 2011-07-08 2015-06-16 Novartis Ag Trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease
WO2013009827A1 (en) 2011-07-13 2013-01-17 Tempero Pharmaceuticals, Inc. Methods of treatment
WO2013009810A1 (en) * 2011-07-13 2013-01-17 Tempero Pharmaceuticals, Inc. Methods of treatment
WO2013009830A1 (en) 2011-07-13 2013-01-17 Tempero Pharmaceuticals, Inc. Methods of treatment
WO2013013113A2 (en) 2011-07-20 2013-01-24 The General Hospital Corporation Histone deacetylase 6 selective inhibitors for the treatment of bone disease
WO2013066839A2 (en) 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods
WO2013066835A2 (en) 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods
WO2013066838A1 (en) 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods
WO2013066833A1 (en) 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods to inhibit histone deacetylase (hdac) enzymes
WO2013066831A1 (en) 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods
ES2606630T3 (es) 2011-11-28 2017-03-24 Novartis Ag Derivados de trifluorometil-oxadiazol novedosos y su uso en el tratamiento de enfermedad
US9480673B2 (en) 2012-03-29 2016-11-01 The Regents Of The University Of Colorado, A Body Corporate Composition and method for treating neurodegenerative disease
US20150119327A1 (en) 2012-04-25 2015-04-30 The Regents Of The University Of California Drug screening platform for rett syndrome
US20150184154A1 (en) 2012-07-05 2015-07-02 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear New treatment for neurodegenerative diseases
CN104894060B (zh) 2014-03-03 2018-11-06 中国科学院上海生命科学研究院 诱导体细胞转分化为神经干细胞的方法及其应用
NZ724030A (en) * 2014-03-12 2017-09-29 Chong Kun Dang Pharmaceutical Corp Novel compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same
US10081624B2 (en) 2014-08-26 2018-09-25 Takeda Pharmaceutical Company Limited Heterocyclic compound
JPWO2016039398A1 (ja) 2014-09-09 2017-06-15 国立大学法人大阪大学 含窒素複素環誘導体、神経保護剤及び癌治療用医薬組成物
SG11201708622UA (en) 2015-02-02 2017-11-29 Forma Therapeutics Inc 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors
CN107848695A (zh) 2015-06-30 2018-03-27 Wm.雷格利 Jr.公司 用于糖果产品的包装和用于形成该包装的方法
WO2017014170A1 (ja) 2015-07-17 2017-01-26 武田薬品工業株式会社 複素環化合物
JP6671456B2 (ja) 2015-07-17 2020-03-25 武田薬品工業株式会社 複素環化合物
AU2016299485B2 (en) 2015-07-27 2019-02-07 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same
ES2935932T3 (es) 2015-07-27 2023-03-13 Chong Kun Dang Pharmaceutical Corp Compuestos de derivados de 1,3,4-oxadiazolsulfonamida como inhibidor de histona desacetilasa 6, y la composición farmacéutica que comprende los mismos
MX376585B (es) * 2015-07-27 2025-03-07 Chong Kun Dang Pharmaceutical Corp Compuestos derivados de sulfamida de 1,3,4-oxadiazol como inhibidor de histona desacetilasa 6, y la composición farmacéutica que comprende los mismos.
AU2016303891B2 (en) 2015-08-04 2019-08-01 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
US10406146B2 (en) 2015-08-25 2019-09-10 Takeda Pharmaceutical Company Limited Heterocyclic compound
HUE061967T2 (hu) 2015-10-12 2023-09-28 Chong Kun Dang Pharmaceutical Corp Hiszton deacetiláz-6 inhibitor oxadiazol-amin származékok és az azokat tartalmazó gyógyászati készítmény
WO2017222952A1 (en) * 2016-06-23 2017-12-28 Merck Sharp & Dohme Corp. 3- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
US20180016314A1 (en) 2016-07-12 2018-01-18 Children's Hospital Medical Center Treatment of disease via transcription factor modulation
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
WO2018215597A1 (en) 2017-05-24 2018-11-29 Orphazyme A/S Heat shock protein inducers and frontotemporal disorders
WO2019027054A1 (en) 2017-07-31 2019-02-07 Takeda Pharmaceutical Company Limited HETEROCYCLIC COMPOUND
EP3664789B1 (en) 2017-08-09 2023-11-22 Children's Hospital Medical Center Methods for treating diseases and nerve injury
WO2019030692A1 (en) 2017-08-10 2019-02-14 Friedrich Miescher Institute For Biomedical Research HDAC6 AND AGGREGATION OF PROTEINS
JP6910984B2 (ja) 2018-03-30 2021-07-28 株式会社ホンダアクセス 脱出ハンマー収容具
KR102316234B1 (ko) 2018-07-26 2021-10-22 주식회사 종근당 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물
FI3870579T3 (fi) 2018-10-22 2025-01-02 Alumis Inc Tyk2-inhibiittoreita ja niiden käyttöjä
US12084436B2 (en) 2019-01-30 2024-09-10 Takeda Pharmaceutical Company Limited Heterocyclic compound
CN114846012B (zh) * 2019-09-27 2024-01-26 武田药品工业株式会社 可用作hdac6抑制剂的2-异吲哚-1,3,4-噁二唑衍生物

Also Published As

Publication number Publication date
ZA202204666B (en) 2023-11-29
WO2021060567A1 (en) 2021-04-01
PH12022550748A1 (en) 2023-11-20
IL291413B1 (en) 2024-11-01
CN114846012B (zh) 2024-01-26
TW202126643A (zh) 2021-07-16
US20240343721A1 (en) 2024-10-17
ECSP22026524A (es) 2022-05-31
CA3156060A1 (en) 2021-04-01
US12384770B2 (en) 2025-08-12
IL291413B2 (en) 2025-03-01
US20210094944A1 (en) 2021-04-01
JP2022552444A (ja) 2022-12-15
US20230183227A1 (en) 2023-06-15
AU2020353984B2 (en) 2025-09-25
KR20220070465A (ko) 2022-05-31
BR112022005595A2 (pt) 2022-07-19
CL2022000763A1 (es) 2023-01-20
CO2022005059A2 (es) 2022-07-08
CN114846012A (zh) 2022-08-02
AU2020353984A1 (en) 2022-04-21
TWI882012B (zh) 2025-05-01
MX2022003490A (es) 2022-04-25
US11958845B2 (en) 2024-04-16
IL291413A (en) 2022-05-01
EP4034536A1 (en) 2022-08-03
JP7602546B2 (ja) 2024-12-18
AU2020353984A2 (en) 2022-08-04
US11453661B2 (en) 2022-09-27
AR120040A1 (es) 2022-01-26

Similar Documents

Publication Publication Date Title
PE20220711A1 (es) Derivados de 2-isoindol-1,3,4-oxadiazol utiles como inhibidores de la histona desacetilasa 6 (hdac6)
AR119651A1 (es) Compuestos heterocíclicos y de heteroarilo para tratar la enfermedad de huntington
AR116604A1 (es) Inhibidores de kras g12c
PE20180529A1 (es) Agonistas de triazol del receptor apj
AR101177A1 (es) Inhibidores de la syk
AR104963A1 (es) Derivados de 2-(pirazolopiridin-3-il)pirimidina como inhibidores de jak
AR087668A1 (es) Derivados de oxazina y su uso en el tratamiento de enfermedades
JP2014511892A5 (es)
PE20161066A1 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
JP2013545791A5 (es)
RU2017116196A (ru) 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1
AR089424A1 (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
BR112016028818A2 (pt) composição farmacêutica, métodos de tratamento de uma doença ou condição, de inibição da atividade de um polipeptídeo de fosfatidilinositol 3-quinase e de inibição de reações imunes excessivas ou destrutivas ou crescimento ou proliferação de células cancerosas, kit, composto, sal, isômero, ou uma mistura farmaceuticamente aceitável do mesmo, e, uso de um composto, um sal, isômero, ou uma mistura farmaceuticamente aceitável do mesmo.
BR112016028819A2 (pt) composição farmacêutica, métodos para tratar uma doença ou condição em um ser humano e para inibir a atividade de um polipeptídeo de fosfatidilinositol 3-quinase e reações imunológicas excessivas ou destrutivas ou o crescimento ou a proliferação de células cancerosas, kit, composto, sal farmaceuticamente aceitável, isômero ou mistura dos mesmos, e, uso de um composto, sal farmaceuticamente aceitável ou mistura dos mesmos.
BR112016028642A2 (pt) composto, composição farmacêutica, método de tratamento de uma doença ou condição, método de inibição da atividade de um polipeptídeo de fosfatidilinositol 3-quinase, método de inibição de reações imunes ou crescimento excessivo ou destrutivo ou de proliferação de células cancerosas, kit, e, uso de um composto, de um sal, de um isômero ou de uma mistura farmaceuticamente aceitável do mesmo.
AR100810A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
CY1119118T1 (el) Θεραπευτικος παραγων για τις διαταραχες της διαθεσης
EA201692266A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
JP2014502988A5 (es)
PE20190806A1 (es) Agonistas heterociclicos del receptor de apelina (apj) y usos de los mismos
AR102217A1 (es) Derivados de benzotiofenilo sustituidos como agonistas de gpr40 para el tratamiento de la diabetes tipo ii
AR082620A1 (es) Compuesto de quinolil amina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar una enfermedad mediada por la inhibicion de la quinasa rip2
MX385276B (es) Tratamiento para la enfermedad de parkinson
RU2014109747A (ru) Морфолино-замещенные производные мочевины или карбамата в качестве ингибиторов mtor
JP2014530197A5 (es)